Domantis Limited

Pulmagen Therapeutics (synergy) Limited

Justian Craig Fox

Mary Frances Fitzgerald

Gregory Paul Winter

Steve Holmes

Ian M Tomlinson

Harry Finch

Armin Sepp

Benjamin P Woolven

Rudolf M T De Wildt

Jennifer Luckett

Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.

Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue

There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

Inhaled combination therapy

Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases

Agents that bind a target in pulmonary tissue for targeting respiratory diseases

Growing community of inventors

Harlow, United Kingdom

Justian Craig Fox